Research Presented by Dr. Thomas Stricker Suggests Oncologists Should Switch to Targeted Treatment if Biomarker Testing Identifies Actionable Mutation Even After First-Line Treatment on...

Aadi Bioscience, Inc. (NASDAQ: AADI), a commercial-stage biopharmaceutical company focused on developing and commercializing precision therapies for genetically-defined cancers with alterations in...

Physician-scientists will present expansive new cancer research, including 33 accepted abstracts NEW BRUNSWICK, N.J., May 25, 2023 /PRNewswire/ -- Rutgers Cancer Institute of New Jersey and...

The company serves as a model for businesses that aim to support veterans, achieving a 240+% increase in veteran hires since 2020 and expanding initiatives to extend assistance in 2023 and beyond...

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient with partial response, resulting in 73% ORR in...